Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Study Summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors

Conditions

Pancreatic Ductal Adenocarcinoma Non-Small Cell Lung Cancer HR+/HER2- Ductal and Lobular Breast Cancer Triple Negative Breast Cancer Colorectal Cancer Soft Tissue Sarcoma

Interventions / Drugs

68Ga-NNS309 177Lu-DFC413

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment180 participants

Primary Completion—

Lead SponsorNovartis Pharmaceuticals

Data Retrieved2026-04-11 02:55:49.152440+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.